Pharma giant Eli Lilly opens strategic technology and innovation hub in Hyderabad

Eli Lilly Hyderabad

American multinational pharma giant Eli Lilly and Company inaugurated a new technology and innovation hub in Hyderabad on August 4, to leverage India's talent pool in artificial intelligence and data sciences and to accelerate its global drug development pipeline.

The 2.20 lakh square foot facility, located in Gachibowli's Phoenix Equinox building, will serve as a strategic center for digital innovation across Lilly's worldwide operations. The US pharmaceutical giant has already hired 100 professionals and plans to expand its headcount to 1,500 in coming years, focusing on AI, automation, cloud computing, and software engineering.

The expansion is central to Lilly’s strategy of embedding advanced digital capabilities to improve efficiency and hasten the journey from lab to patient.

“This expansion brings together top talent in AI, data science, and engineering to build the digital foundation that will accelerate the discovery and delivery of innovative medicines,” said Diogo Rau, Executive Vice President and Chief Information and Digital Officer for Eli Lilly, at the inauguration. “Hyderabad offers the perfect blend of deep technical expertise and a spirit of collaboration, making it a natural partner in our mission”.

Read More: Eli Lilly says India response to obesity drug Mounjaro is 'positive'

The investment marks a significant win for Hyderabad, reinforcing its status as a global hub for both life sciences and technology sectors. Government officials said the move is a validation of the state's business-friendly ecosystem.

“We are delighted to welcome Lilly to Hyderabad’s growing life sciences ecosystem,” said A Revanth Reddy, the Chief Minister of Telangana. “The inauguration of this new site further reinforces the city’s position as a global hub for healthcare innovation”.

The Hyderabad site will support Lilly’s global efforts in tackling major health challenges, including redefining care for diabetes and obesity, advancing the fight against Alzheimer's disease, and developing treatments for complex cancers and immune disorders.